Lasofoxifene,Fulvestrant
Sermonix,pfizer
['breast', 'bcsm', 'lasofoxifene', ' fulv']
the nonsteroidal selective estrogen receptor modulator lasofoxifene resulted in better clinical benefit vs fulvestrant in patients with estrogen receptor (er) positive, her2-negative, esr1-mutant metastatic breast cancer. #bcsm #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.